Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 6/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.38 |
| ▸ | POLB | P06746 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | HTT | P42858 | 3/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3605954 | 1.00 | SLC22A12 (0.40) | SLC22A12MAPTLMNAKMT2APOLB | |
| SCHEMBL3603076 | 0.84 | SLC22A12 (0.46) | SLC22A12MAPTNPC1 | |
| SCHEMBL3608067 | 0.83 | SLC22A12 (0.47) | SLC22A12MAPTLMNAKMT2APOLB | |
| SCHEMBL3608064 | 0.83 | SLC22A12 (0.47) | SLC22A12MAPTLMNAKMT2APOLB | |
| SCHEMBL3600487 | 0.82 | SLC22A12 (0.41) | SLC22A12MAPTALDH1A1NPC1HPGD | |
| SCHEMBL5183568 | 0.81 | SLC22A12 (0.38) | SLC22A12NPC1 | |
| SCHEMBL15785632 | 0.79 | MAPT (0.40) | MAPTLMNAKMT2APOLBMEN1 | |
| SCHEMBL16778361 | 0.79 | MAPT (0.40) | MAPTLMNAKMT2APOLBMEN1 | |
| SCHEMBL3597241 | 0.78 | SLC22A12 (0.43) | SLC22A12MAPTLMNAKMT2APOLB | |
| SCHEMBL3597239 | 0.78 | SLC22A12 (0.43) | SLC22A12MAPTLMNAKMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723348-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-05-25 | — | — | US | disclosed |
| US-7723348-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-05-25 | — | — | US | disclosed |
| US-7432266-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432266-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-10-07 | — | — | US | disclosed |
| US-20080207660-A1 | PHOSPHODIESTERASE 4 INHIBITORS | HOPPER ALLEN | 2008-08-28 | — | — | US | disclosed |
| US-20080207660-A1 | PHOSPHODIESTERASE 4 INHIBITORS | HOPPER ALLEN | 2008-08-28 | — | — | US | disclosed |
| WO-2007123953-A2 | PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2007-11-01 | — | — | WO | disclosed |
| US-20070254913-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2007-11-01 | — | — | US | disclosed |
| US-20070254913-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2007-11-01 | — | — | US | disclosed |
| EP-1799673-A1 | PYRAZOLE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS | Memory Pharmaceuticals Corporation (US) | 2007-06-27 | — | — | EP | disclosed |
| US-20060154960-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2006-07-13 | — | — | US | disclosed |
| WO-2006044528-A1 | PYRAZOLE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254913-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE12 | SLC22A12 2455/4885MAPT 3815/4885LMNA 3738/4885 |
| US-20080207660-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE4B, PDE12 | SLC22A12 2455/4885MAPT 3815/4885LMNA 3738/4885 |
| US-20060154960-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE12 | SLC22A12 2455/4885MAPT 3815/4885LMNA 3738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.